The number of CD34+ cells mobilized into the peripheral blood can predict the quality of subsequent collections.
暂无分享,去创建一个
T. Holyoake | R. Green | J. Barr | C. Pearson | M. Alcorn | E. Farrell
[1] K. Schulman,et al. Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Gratwohl,et al. Blood and marrow transplantation activity in Europe 1996 , 1998, Bone Marrow Transplantation.
[3] G. Salles,et al. High CD34+ Cell Counts Decrease Hematologic Toxicity of Autologous Peripheral Blood Progenitor Cell Transplantation , 1998 .
[4] E. Shpall,et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. , 1997, Blood.
[5] E. Ball,et al. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation , 1997, Bone Marrow Transplantation.
[6] D. Huhn,et al. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] P. Lacor,et al. The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis. , 1996, Bone marrow transplantation.
[8] R. Hargreaves,et al. When to harvest peripheral-blood stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] N. Schmitz,et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.
[10] L. Schwartzberg,et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. , 1995, Blood.
[11] R. Storb,et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Hunter,et al. Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF. , 1995, Bone marrow transplantation.
[13] R. Storb,et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of engraftment after transplantation , 1994, British journal of haematology.
[14] H. Goldschmidt,et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. , 1994, Blood.
[15] L. To,et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. , 1992, Bone marrow transplantation.
[16] A. Pileri,et al. GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION , 1989, The Lancet.